Microbiome player snags M from Pfizer, Roche to expand computational biology platform

Second Genome has pulled in $42.6 million to expand its Microbiome Discovery Platform. The Series B round, which was co-led by the VC wings of Pfizer ($PFE) and Roche ($RHHBY), will give Second Genome the financial clout to use its computational biology-enabled discovery platform in a growing list of indications. San Francisco, CA-based Second Genome has established its status as a forerunner in the emerging microbiome sector on the strength of the platform and the candidates it has discovered. The next step in the evolution of the platform, which draws on genomics technologies, computational biology and phenotypic screening to link materials from the microbiome to human disease, is to broaden its therapeutic scope. Second Genome is keen to apply the discovery platform to indications in which barrier function, insulin sensitivity…


Link to Full Article: Microbiome player snags M from Pfizer, Roche to expand computational biology platform